The Combined Application of PARP Inhibitor and PD-1/PD-L1 Inhibitor in the Treatment of Ovarian Cancer

doi:10.12280/gjfckx.20230289

Abstract

Abstract:

Ovarian cancer is one of the three major gynecological malignancies and the most lethal malignancy of female reproductive system. At present, the main treatment methods for ovarian cancer are primary debulking surgery and platinum-based chemotherapy, but the recurrence rate and drug resistance rate remain high. In recent years, the development of tumor immunotherapy has progressed rapidly, especially the research on programmed death-1(PD-1) and programmed death-ligand 1 (PD-L1), which has been achieved on a variety of tumors. However, many clinical trials have found that PD-1/PD-L1 inhibitors alone are not effective in treating ovarian cancer. The poly (ADP-ribose) polymerase inhibitor (PARPi) is a type of targeted medicine that kills tumor cells through synthetic lethal effect. Recent studies have shown that PARPi has immunomodulatory effects in addition to its own cytotoxic effects, and can have a synergistic effect with PD-1/PD-L1 inhibitors, and the combination of the two can significantly improve patient prognosis. Therefore, this article reviews the research progress on the mechanism of action and clinical application of PD-1/PD-L1 inhibitor combined with PARPi in the treatment of ovarian cancer.

Key words: Ovarian neoplasms, Immunotherapy, Molecular targeted therapy, Poly(ADP-ribose) polymerase inhibitors, Immune checkpoint inhibitors, PD-1/PD-L1 inhibitor

GUO Jing-jing, ZHANG Yun-feng, WANG Yue. The Combined Application of PARP Inhibitor and PD-1/PD-L1 Inhibitor in the Treatment of Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2023, 50(5): 568-572.

References 35

[1]	Chen J, Wei Z, Fu K, et al. Non-apoptotic cell death in ovarian cancer: Treatment, resistance and prognosis[J]. Biomed Pharmacother, 2022, 150:112929. doi: 10.1016/j.biopha.2022.112929.
[2]	Zhang T, Zheng S, Liu Y, et al. DNA damage response and PD-1/PD-L1 pathway in ovarian cancer[J]. DNA Repair(Amst), 2021, 102:103112. doi: 10.1016/j.dnarep.2021.103112.
[3]	Yang Y, Zhao T, Chen Q, et al. Nanomedicine Strategies for Heating "Cold" Ovarian Cancer (OC): Next Evolution in Immunotherapy of OC[J]. Adv Sci(Weinh), 2022, 9(28):e2202797. doi: 10.1002/advs.202202797.
[4]	Wanderley C, Correa TS, Scaranti M, et al. Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical Implications[J]. Front Immunol, 2022, 13:816642. doi: 10.3389/fimmu.2022.816642.
[5]	Majidpoor J, Mortezaee K. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives[J]. Clin Immunol, 2021, 226:108707. doi: 10.1016/j.clim.2021.108707.
[6]	Świderska J, Kozłowski M, Kwiatkowski S, et al. Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points[J]. Cancers(Basel), 2021, 13(23):6063. doi: 10.3390/cancers13236063.
[7]	Nagasaki J, Togashi Y. A variety of ′exhausted′ T cells in the tumor microenvironment[J]. Int Immunol, 2022, 34(11):563-570. doi: 10.1093/intimm/dxac013.
[8]	Khatoon E, Parama D, Kumar A, et al. Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy[J]. Life Sci, 2022, 306:120827. doi: 10.1016/j.lfs.2022.120827.
[9]	Shiravand Y, Khodadadi F, Kashani SMA, et al. Immune Checkpoint Inhibitors in Cancer Therapy[J]. Curr Oncol, 2022, 29(5):3044-3060. doi: 10.3390/curroncol29050247. pmid: 35621637
[10]	Matulonis UA, Shapira-Frommer R, Santin AD, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study[J]. Ann Oncol, 2019, 30(7):1080-1087. doi: 10.1093/annonc/mdz135. pmid: 31987374
[11]	Zhu J, Yan L, Wang Q. Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis[J]. J Ovarian Res, 2021, 14(1):112. doi: 10.1186/s13048-021-00862-5. pmid: 34454562
[12]	Xie T, Dickson KA, Yee C, et al. Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival[J]. Cancers (Basel), 2022, 14(19):4621. doi: 10.3390/cancers14194621.
[13]	Lau CH, Seow KM, Chen KH. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review[J]. Int J Mol Sci, 2022, 23(15):8125. doi: 10.3390/ijms23158125.
[14]	Musacchio L, Cicala CM, Camarda F, et al. Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?[J]. ESMO Open, 2022, 7(4):100536. doi: 10.1016/j.esmoop.2022.100536.
[15]	Ou L, Zhang A, Cheng Y, et al. The cGAS-STING Pathway: A Promising Immunotherapy Target[J]. Front Immunol, 2021, 12:795048. doi: 10.3389/fimmu.2021.795048.
[16]	Gupta T, Vinayak S, Telli M. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer[J]. Breast Cancer Res Treat, 2023, 197(1):51-56. doi: 10.1007/s10549-022-06780-4.
[17]	Yu R, Zhu B, Chen D. Type I interferon-mediated tumor immunity and its role in immunotherapy[J]. Cell Mol Life Sci, 2022, 79(3):191. doi: 10.1007/s00018-022-04219-z. pmid: 35292881
[18]	Revythis A, Limbu A, Mikropoulos C, et al. Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer[J]. Int J Environ Res Public Health, 2022, 19(14):8577. doi: 10.3390/ijerph19148577.
[19]	Banerjee S, Moore KN, Colombo N, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2021,22(12):1721-1731. doi: 10.1016/S1470- 2045(21)00531-3.
[20]	Poveda A, Floquet A, Ledermann JA, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2021,22(5):620-631. doi: 10.1016/S1470-2045(21)00073-5.
[21]	Li H, Liu ZY, Wu N, et al. PARP inhibitor resistance: the underlying mechanisms and clinical implications[J]. Mol Cancer, 2020, 19(1):107. doi: 10.1186/s12943-020-01227-0. pmid: 32563252
[22]	Chardin L, Leary A. Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1[J]. Front Oncol, 2021, 11:795547. doi: 10.3389/fonc.2021.795547.
[23]	Maiorano BA, Lorusso D, Maiorano M, et al. The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy[J]. Int J Mol Sci, 2022, 23(7):3871. doi: 10.3390/ijms23073871.
[24]	Scirocchi F, Strigari L, Di Filippo A, et al. Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis[J]. Int J Mol Sci, 2022, 23(22):14496. doi: 10.3390/ijms232214496.
[25]	Wu Z, Cui P, Tao H, et al. The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors[J]. Clin Med Insights Oncol, 2021, 15:1179554921996288. doi: 10.1177/1179554921996288.
[26]	Zhang Y, Cui Q, Xu M, et al. Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer[J]. Front Immunol, 2022, 13:901772. doi: 10.3389/fimmu.2022.901772.
[27]	Huang JL, Chang YT, Hong ZY, et al. Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy[J]. Int J Mol Sci, 2022, 23(6):3238. doi: 10.3390/ijms23063238.
[28]	Batchu RB, Gruzdyn OV, Kolli BK, et al. IL-10 Signaling in the Tumor Microenvironment of Ovarian Cancer[J]. Adv Exp Med Biol, 2021, 1290:51-65. doi: 10.1007/978-3-030-55617-4_3. pmid: 33559854
[29]	Yélamos J, Moreno-Lama L, Jimeno J, et al. Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies[J]. Cancers(Basel), 2020, 12(2):392. doi: 10.3390/cancers12020392.
[30]	Pantelidou C, Sonzogni O, De Oliveria Taveira M, et al. PARP Inhibitor Efficacy Depends on CD8⁺ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer[J]. Cancer Discov, 2019, 9(6):722-737. doi: 10.1158/2159-8290.CD-18-1218.
[31]	Lampert EJ, Zimmer A, Padget M, et al. Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase Ⅱ Study[J]. Clin Cancer Res, 2020, 26(16):4268-4279. doi: 10.1158/1078-0432.CCR-20-0056. pmid: 32398324
[32]	Drew Y, De JM, Hong SH, et al. An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)[J]. Gynecol Oncol, 2018, 149:246-247. doi:10.1016/j.ygyno.2018.04.555.
[33]	Konstantinopoulos PA, Waggoner S, Vidal GA, et al. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma[J]. JAMA Oncol, 2019, 5(8):1141-1149. doi: 10.1001/jamaoncol.2019.1048.
[34]	Pusztai L, Yau C, Wolf DM, et al. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage Ⅱ/Ⅲ breast cancer: Results from the adaptively randomized I-SPY2 trial[J]. Cancer Cell, 2021, 39(7):989-998.e5. doi: 10.1016/j.ccell.2021.05.009. pmid: 34143979
[35]	Monk BJ, Coleman RL, Fujiwara K, et al. ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer[J]. Int J Gynecol Cancer, 2021, 31(12):1589-1594. doi: 10.1136/ijgc-2021-002933. pmid: 34593565